Carla Lamb, MD
Pulmonary Disease · Burlington, MANPI 1508963208
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Boston Scientific at 44.4% of the total. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $437.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$12K
- Cook Incorporated$6K
- Intuitive Surgical$4K
- Pulmonx Corporation$3K
- Noah Medical Corporation$780
- ERBE USA Inc$383
- plus $1K from 8 others
Across 39 payments — averaging $4072.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Galvanize Therapeutics, Inc$87K
- CSL Behring$48K
- Boston Scientific$16K
- Gyrus ACMI, Inc.$6K
- Spiration, Inc.$2K
What the payments were for
- Consulting fees$12,21546%
- Speaking & faculty fees$9,47536%
- Travel & lodging$2,93411%
- Food & beverage$2,0338%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $11,843 |
| Cook Incorporated | 3 | $5,649 |
| Intuitive Surgical | 15 | $4,002 |
| Pulmonx Corporation | 7 | $2,987 |
| Noah Medical Corporation | 8 | $780 |
| ERBE USA Inc | 1 | $383 |
| Cook Medical LLC | 3 | $317 |
| AstraZeneca | 3 | $252 |
| Medtronic | 2 | $197 |
| GSK | 4 | $91 |
| Steris Corporation | 1 | $89 |
| Olympus America Inc. | 1 | $50 |
| Johnson & Johnson | 1 | $15 |
| Ambu Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL PULMONARY$9,540
- Melker$4,675
- Da Vinci Surgical System$3,115
- ZEPHYR ENDOBRONCHIAL VALVE$2,750
- CHARTIS CATHETER$1,500
- PULMONX CHARTIS TABLET CONSOLE$1,500
- ZEPHYR DELIVERY CATHETER$1,500
- Blue Rhino$1,212
- ACQUIRE$855
- EXALT BX 2$800
- GENERAL - THERAPIES$570
- DA VINCI SP$500
- ERBE$383
- GALAXY$298
- Signet$154
- Pulmonx Endobronchial Valve EBV$116
How this compares
$26,657 in reported general payments places this provider in the 90th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 177 | $193,656 |
| Pirfenidone | 28 | $97,844 |
| Breo ElliptaFluticasone/Vilanterol | 83 | $51,346 |
| Advair HfaFluticasone Propion/Salmeterol | 65 | $34,886 |
| Spiriva HandihalerTiotropium Bromide | 30 | $26,711 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $22,079 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $19,689 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $14,560 |
| Arnuity ElliptaFluticasone Furoate | 35 | $14,077 |
| DuleraMometasone/Formoterol | 12 | $8,171 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 161 | $6,816 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $4,963 |
| Wixela InhubFluticasone Propion/Salmeterol | 38 | $4,614 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,610 |
| Ventolin HfaAlbuterol Sulfate | 25 | $2,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $91 | $300,846356 claims |
| AstraZenecaSymbicort | $252 | $14,56024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Burlington
- Adam SmithBurlington$296K
- Cyrus KholdaniBurlington$16K
- Yaron GoldmanWorcester$843K
- Sarah GrantBrookline$678K
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Fernando MartinezWorcester$375K
- Ana CojocaruFall River$364K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.